【直播】There is No Perfect Drug Molecule: A Case Study

职场   2024-11-14 21:09   江苏  



Drug discovery and development is a long and arduous journey and only a tiny fraction of drug candidates can survive all clinical trials and reach the market. For a drug candidate to be selected and successfully developed, it has to meet the requirements of numerous drug-like properties in biology, pharmacology, pharmacokinetics, toxicology, and manufacturability. Every drug candidate has some flaws and there's no perfect molecule that can meet all these requirements. Drug developers have to balance all these properties and make calculated decisions when advancing a drug candidate. 

From drug metabolism, pharmacokinetics, and clinical pharmacology perspectives, this presentation will highlight why there are no ideal PK profiles and no perfect molecules and how we can manage the flaws in every drug candidate. The case and story of avacopan, a recently approved drug which had many near-death experiences before reaching the market, will be discussed. 

活动组织:Ethan Xu





Event Details


主题:【BioSpark 论药】There is No Perfect Drug Molecule: A Case Study


时间:2024年11月16日 Sat 9:00 PM(EST)/ 2024年11月17日 周日 早上10:00 AM(北京时间)


地点:zoom meeting(扫描二维码获得zoom注册链接或点击文末“阅读原文”



Speaker Intro

Shichang Miao, PhD

Shichang Miao, PhD, is a seasoned drug discovery scientist, drug developer and biotech investor. During his career, he worked at several biotech companies in the San Francisco Bay Area, including Tularik, ChemoCentryx and Amgen. At ChemoCentryx, as Vice President of Preclinical Development & Clinical Pharmacology, he led his team to conduct the preclinical assessment and clinical pharmacology studies for the development of Tavneos® (avacopan), which was approved in 2021 by the FDA for the treatment of ANCA-associated vasculitis, leading to the acquisition of ChemoCentryx by Amgen in 2022. He has also been a managing partner of Rivermount VC Fund, an advisor to Stanford University's SPARK translational medicine program, and a Bio Screening Committee member of Life Science Angels. He is the founder and president of Pharmaceutical & BioScience Society International (PBSS), with chapters in the San Francisco Bay Area, San Diego, Boston, Vancouver, Korea, and soon Seattle.


He received his PhD in organic chemistry and post-doctoral training in biochemistry at the University of British Columbia (Vancouver, Canada).



活动直播伙伴































About us

BioSpark

BioSpark Group成立于2019年8月,是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流,建立富有合作和互助精神的社群生态环境,实现学术和企业的跨界交流及思想碰撞,从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。

BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.

成为BioSpark会员:BioSpark期待您的加入--会员推荐与申请 

https://www.biospark.org/

Follow us on Twitter: 
https://twitter.com/BioSpark_Group

Follow us on LinkedIn: 
https://www.linkedin.com/company/biospark-group

BioSpark events Calendar: 
https://tinyurl.com/tcwy44t6

Email us: info@BioSpark.org

合作或加入日常活动交流群,请添加小助手微信号:BioSpark-Group



同写意
一个以新药创制为核心,汇集国内一流研发精英的大型交流与价值分享平台。“同筑技术人生路,写意中国新药魂”是同写意的初衷与愿景。秉承汇集“一线、一流”,讲求“实用、实在、时效”的原则。
 最新文章